We noted with interest the recent study by Baracchini et al,1 which reports a single-center, single-surgeon experience of eversion carotid endarterectomies (CEA) and factors associated with increased perioperative bleeding complications, including re-exploration for bleeding. The study concludes that preoperative treatment with clopidogrel, when used either alone or combined with aspirin was associated with an increased incidence of bleeding. The authors additionally conclude that aspirin and ticlopidine, when used alone preoperatively were also associated with an increased incidence of neck hemorrhage following CEA. Review of the study sample, however, reveals that only 110 patients were taking clopidogrel alone within 1 day of surgery and that only an additional 10 patients were taking combined therapy (clopidogrel ϩ aspirin). Furthermore, only 95 patients were taking aspirin alone at the time of CEA, making definitive conclusions regarding these commonly used antiplatelet agents more difficult.By comparison, in a recent study by the Vascular Study Group of New England, 2 we evaluated 5264 carotid endarterectomies, performed by 66 surgeons treated at 15 academic and community centers. We found that preoperative aspirin (asa; n ϭ 3823), clopidogrel (n ϭ 147), or dual antiplatelet therapy (asa ϩ clopidogrel; n ϭ 708) use was not associated with any increase in re-exploration for bleeding after CEA (asa 1.2%, clopidogrel 0.7%, asa ϩ clopidogrel 1.4%; P ϭ .84). 2 Based on this data, we do not believe that aspirin or clopidogrel increases serious bleeding complications and it remains our practice to routinely perform CEA in patients taking antiplatelet therapy at the time of surgery, for which there is sufficient evidence from both randomized controlled trials and our study group to justify therapy given their impact on reducing stroke. [3][4][5][6] The different conclusion reached by Baracchini et al could also relate to their nonuse of protamine to reverse heparin during CEA, potentially amplifying bleeding risk if antiplatelet agents are also being used. Our data has previously shown a significant decrease in re-exploration for bleeding after CEA (n ϭ 4587) when protamine is used, independent of antiplatelet agents (protamine 0.64% vs no protamine 1.66%; P ϭ .001). 7 Accordingly, we believe that recent studies support the safe use of both antiplatelet therapy at the time of CEA and the use of protamine to reverse heparin intraoperatively.